Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 8, pp. 710-721
Open Access | Times Cited: 151

Showing 1-25 of 151 citing articles:

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 68
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzmán Alonso, Se Hyun Kim, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 271-278
Open Access | Times Cited: 53
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 19
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 14
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Stefania Napolitano, Giulia Martini, Davide Ciardiello, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 7, pp. 664-676
Closed Access | Times Cited: 13
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Nadia Saoudi, Javier Ros, Iosune Baraibar, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 412-412
Open Access | Times Cited: 12
If it’s a target, it’s a pan-cancer target: Tissue is not the issue
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 11
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 10
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives
Christos Adamopoulos, Donatella Delle Cave, Athanasios G. Papavassiliou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1631-1631
Open Access | Times Cited: 9
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Anupriya Singhal, Hannah C. Styers, Jonathan Rub, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2122-2134
Closed Access | Times Cited: 9
Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket
Johannes Morstein, Vickie Bowcut, Micah C. Fernando, et al.
Cell (2024)
Open Access | Times Cited: 9
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 9
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top